Pharmerging Contract Manufacturing Market: Expected To Observer Major Growth By 2026

Pharmerging Contract Manufacturing Market Intelligence Report Offers Growth Prospects March 2017

About Future Market Insights Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client.

Research Capabilities    

Customized Research Syndicated Research Investment Research

Social Media Research

Customized Research Syndicated Research Investment Research Social Media Research

Sector Coverage    

Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment

   

Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas

Subscription Information

For detailed subscription information please contact Hari. T (Sr. Manager - Global Business Development) T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com

2

Research Methodology (1/2) Systematic Research Approach 1 Market profiling

2 Formulating discussion guide

3 Developing list of respondents

4

In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc. PMR formulates a detailed discussion guide to conduct expert and industry interviews PMR develops a list of industry players (manufacturers), distributors, retailers and industry experts

Data collection

PMR conducts interviews with industry experts, industry players, distributors and retailers

Data validation

Data is validated by triangulation method, wherein secondary, primary and PMR analysis contribute to the final data

5 6

Data analysis

Insights

7

Data is scrutinized using MS-Excel to obtain qualitative and quantitative insights about the industry PMR delivers industry insights and information in the required format (PDF)

Data Collection

   

Research & Intelligence

Data Filter & Analysis

Identifying key opinion leaders Questionnaire design In-depth interviews Coverage across value chain

Actionable Insights

A Primary Research

     

B SOLUTION     

Market participants Key strengths Product portfolio Mapping as per value chain Key focus segments

Primary Research #    

Linkedin Zoominfo Salesforce Avention

Business Solution

Desk Research

C

Key industry experts Channel study Developments Market dynamics Products Conclusions

Company Analysis

Secondary Research #    

Company websites Company annual reports White papers Financial reports

Paid Publications#    

Factiva GBI Genios Meltwater

# includes sources of databases

3

Pharmerging Contract Manufacturing Market Pharmerging markets indicate the most promising emerging markets in the pharmaceutical domain. Most of these markets are currently exhibiting growth rates moderate to high indicating sustainable demand prospects. The global pharmaceutical market is projected to expand at CAGR of 4â&#x20AC;&#x201C;7% between 2015 and 2026 to reach US$1.5 trillion by 2026. This indicates revenues from companies at ex-manufacturer price levels excluding rebates and discounts. Industry experts note that the U.S. and pharmerging markets are expected to account for more than 60% of sales and 80% of sales growth over the next five years. Contract manufacturing of pharmaceuticals is witnessing steady acceleration in pharmerging markets given high demand for medicines in these countries. For example, consumer medicines form a substantially large portion of pharmerging markets and manufacturers want to source the production of these medicines in the target market themselves. Given the growing complexity in supply-chain of highly potent drugs (both small molecules and biologics); there is a growing trend of outsourcing early-stage analytical, formulation, and commercial development of the medicines. This shift offers CDMOs more opportunities to partner and offer services within the drug product lifecycle. Specifically experts notes that outsourcing the bulk manufacturing of drugs is gradually gaining traction in countries in Asia-Pacific. Pharmerging Contract Manufacturing Market: Drivers and Restraints Growing demand for generics in pharmerging markets due to affordability issues is the single most important revenue growth driver of the CMOs in pharmerging markets. Favorable government policies promoting localization are expected to create pull factors for generally manufacturers of generic products rather than originals. Companies having large portfolios, integrated distributors, strong stakeholder relationships, and quick decision-making processes in place are expected to witness dynamic growth ÂŠ2015 Future Market Insights, All Rights Reserved

4

Pharmerging Contract Manufacturing Market compared to others. Other success factors of CMOs include proven record of accomplishment in continuity of supply, unchallengeable quality, competitive pricing and presence of adequate skilled workforce. Request For Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2482

Barriers include non-availability of adequate sterile infrastructure to manufacture injectable drugs and other aseptic formulations. Availability of skilled labor to assist manufacturing of highly potent APIs, cytotoxic drugs, other biologics are factors expected to halt production. Other barriers include limited access to foreign capital, lack of transparency in emerging markets and fluctuations in government policies. Pharmerging Contract Manufacturing Market: Segmentation Global pharmerging contract manufacturing market can be segmented in multiple ways. A few these segmentation approaches are based on Product, Class, Therapeutic Area, and, CMO type. Based on the product class, the pharmerging contract manufacturing market is segmented into the following: ď&#x192;&#x2DC; Branded Drugs

5

Pharmerging Contract Manufacturing Market  Branded Generics  Generics Based on the drug class, market is segmented as: Small molecule Drugs 

Generic Drugs



Highly-potent drugs and cytotoxic drugs

6

Pharmerging Contract Manufacturing Market Based on the therapeutic class, the market is segmented into the following:  Cardiovascular  Oncology  Diabetes  Infectious Diseases  Others Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-2482 Pharmerging Contract Manufacturing Market: Market Overview The market for CMOs is gaining traction across regions and market given CMOs are increasingly being considered strategic partners, in production through sharing greater amounts of the portfolio volume, and less as step-in organizations to smooth out manufacturing peaks.

7

Pharmerging Contract Manufacturing Market Geographically, pharmerging contract manufacturing market is classified into regions viz. Latin America, Europe, APAJ, Middle East and Africa. In terms of geography, Europe accounts for the largest market share followed by APAC. Favorable policies, regulations and sophisticated healthcare infrastructure with increasing FDA approvals is expected to drive revenue growth of the market in the near future. Markets in Asia Pacific represent the fastest growth for generic drugs owing to growing number of CMOs, CROs and CDMOs coupled with development of favorable infrastructure across countries in the region. Few key players in pharmerging contract manufacturing market are Cipla, Piramal Healthcare, Aurobindo, Jubilant Life Sciences, Zydus Cadila, Alkem, Intas, Lupin, Torrent, FDC, etc. apart from includes and others. Some of China’s leading CMOs include Asymchem Laboratories, Beijing Second Pharmaceutical, Chongqing Huapont Pharmaceutical, Porton Fine Chemicals, Shandong Xinhua Pharmaceutical, etc. These players are entering into strategic collaborations, mergers & acquisitions, and product portfolio expansions, which are their key sustainability strategies to maintain their profit margins in the long run. Also many startup companies’ have entered in this lucrative market space to capitalize over the opportunities present in therapeutic laser system market. Browse Full Report@ http://www.futuremarketinsights.com/reports/pharmerging-contract-manufacturing-market

8

To know more about us, please visit our website:

www.futuremarketinsights.com For sales queries or new topics email us on:

sales@futuremarketinsights.com For media queries, contact the press office at press@futuremarketinsights.com For other queries contact:

Harish Tiwari (General Manager & Global Head Business Development) Future Market Insights: 3rd Floor, 207 Regent Street, London W1B 3HH T: +44 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com

Thank You Future Market Insights Global & Consulting Private Limited (FMI)

9

Turn static files into dynamic content formats.

Create a flipbook